Sol-Gel Technologies Ltd. (SLGL) stock surged +6.44%, trading at $77.70 on NASDAQ, up from the previous close of $73.00. The stock opened at $75.20, fluctuating between $74.10 and $79.30 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 04, 2026 | 74.74 | 78.53 | 73.50 | 77.70 | 11.55K |
| Apr 30, 2026 | 71.07 | 77.20 | 70.90 | 74.04 | 16.62K |
| Apr 29, 2026 | 71.90 | 73.50 | 68.25 | 71.40 | 26.57K |
| Apr 28, 2026 | 76.00 | 76.00 | 67.35 | 70.92 | 37.24K |
| Apr 27, 2026 | 78.00 | 79.03 | 71.09 | 77.00 | 21.07K |
| Apr 23, 2026 | 70.40 | 73.10 | 69.90 | 72.30 | 53.52K |
| Apr 22, 2026 | 75.01 | 75.59 | 70.52 | 73.48 | 29.46K |
| Apr 21, 2026 | 72.50 | 76.43 | 70.00 | 75.89 | 18.13K |
| Apr 20, 2026 | 73.87 | 75.00 | 69.61 | 70.00 | 26.39K |
| Apr 17, 2026 | 75.70 | 77.22 | 72.83 | 73.87 | 40.24K |
| Apr 16, 2026 | 80.70 | 81.00 | 75.00 | 75.32 | 42.88K |
| Apr 14, 2026 | 76.00 | 77.99 | 74.41 | 76.50 | 32.54K |
| Apr 13, 2026 | 73.20 | 77.88 | 72.02 | 74.41 | 113.18K |
| Apr 10, 2026 | 74.05 | 77.80 | 71.90 | 74.86 | 72.79K |
| Apr 09, 2026 | 72.35 | 75.10 | 71.15 | 72.02 | 72.43K |
| Apr 08, 2026 | 72.67 | 75.50 | 71.22 | 74.50 | 155.77K |
| Apr 07, 2026 | 72.30 | 75.35 | 69.02 | 71.11 | 84.96K |
| Apr 06, 2026 | 77.24 | 82.90 | 72.90 | 74.34 | 63.64K |
| Apr 02, 2026 | 82.90 | 84.60 | 77.46 | 79.46 | 80.1K |
| Apr 01, 2026 | 79.89 | 85.33 | 79.89 | 83.50 | 56.96K |
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Employees | 34 |
| Beta | 1.27 |
| Sales or Revenue | $1.55M |
| 5Y Sales Change% | 6.946% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep